 |
|||
| Url | https://cimne.com/sgp/rtd/Project.aspx?id=922 | ||
|
|||
| Acronym | ADAPTA | ||
| Project title | Modelos computacionales para la evaluacion y tratamiento de disecciones de aorta: diseño de dispositivos endovasculares Computational models for assessment and treatment aortic dissections: evaluation and design endovascular devices | ||
| Reference | PID2021-122518OB-I00 | ||
| Principal investigator |
Eduardo SOUDAH PRIETO - esoudah@cimne.upc.edu
Joaquin Alberto HERNANDEZ ORTEGA - jhortega@cimne.upc.edu |
||
| Start date | 01/09/2022 | End date | 31/08/2025 |
| Coordinator | CIMNE | ||
| Consortium members |
|
||
| Program | P.E. para Impulsar la Investigación Científico-Técnica y su Transferencia | Call | Proyectos Generación de Conocimiento 2021 |
| Subprogram | Subprograma Estatal de Generación de Conocimiento | Category | Nacional |
| Funding body(ies) | MICINN | Grant | $151,492.00 |
| Abstract | It should be remarked that each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in theEuropean Union (EU). CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU. Aortic dissections(AD) represent a major challenge in CVD field. AD is the most common and catastrophic event that can occur in the aorta. AD is a results from the tearing of the inner layer of the aortic wall. As a result, innovation in AD has been barely incremental in last years. Nevertheless, the global market for aortic devices is valued at 2 billion dollars in 2020 and is projected to reached more than 2.4 billion dollars in 2025, growing at a CARG of 3.7% due to aging population and increased predominance of endovascular procedures. These procedures offer inferior risks and recovery time compared to conventional open surgery but still present several limitations, secondary effects and elevates mortality. For that reason, improving the design and the treatment decision by advanced computer-aided technology will have a highly beneficial impact on society. Overall CVD is estimated to cost the EU economy 210 billion a year. Of the total cost of CVD in the EU, around 53% (111 billion) is due to health care costs, 26% (54 billion) to productivity losses and 21% (45 billion) to the informal care of people with CVD.The vision of the IPs of the project is that the clinicians (in collaboration with the engineers) will be able to make decisions more aware about which will be best AD treatment for each patient, reducing as a consequence the risk of future complications. In ADAPTA project we wish to develop a computational framework able to help the engineer/physicians in designing deployer devices (and its verification and validation (V&V)) in an in-silico and in a patient-specific environment, as well in contributing in the understanding of how the current and new treatments affect in the evolution of the AD. Special attention will be paid to the AD patch porous treatment. Another important aspect that we want to cover in the project is the assessment of the AD based on the structural and hemodynamic parameters. These hemodynamic and structural parameters can help the clinicians in understanding of the silent evolution of the AD, and in its fatal outcome (wall rupture). The general goal is to contribute significantly in assisting in the diagnosis, treatment and monitoring of AD. To achieve this general goal, we shall set the following two main objectives: - Develop a computational framework for clinical assessment of AD based on an FSI-embedded approach. - Analysis, validation and verification of a new medical devices (a porous patch) for Aortic Dissection Treatment. ADAPTA project will provide more objective information about the AD treatment procedure, helping avoiding re-intervention. This in turn will support a paradigm shift, away from predefined clinical indications, and towards personalization of care based on ones physiology. This will surely have a beneficial impact on all the major healthcare stakeholders. Besides, the contributions of the ADAPTA project to improve healthcare are multi-factorial, and will result on a more predictive, individualized, effective and safer healthcare. In addition, the simulation framework will provide an individualized mechanical interpretation of the AD treatment taking into account the patient context: from Lab to the Patient. | ||
| Ayuda PID2021-122518OB-I00 del proyecto financiado por MCIN/AEI/10.13039/501100011033/ y por "FEDER: Una manera de hacer Europa" | |||